These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
128 related articles for article (PubMed ID: 24524102)
1. Dolutegravir, an HIV integrase inhibitor for the treatment of HIV infection. Temesgen Z; Talwani R; Rizza SA Drugs Today (Barc); 2014 Jan; 50(1):7-14. PubMed ID: 24524102 [TBL] [Abstract][Full Text] [Related]
2. Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. Shah BM; Schafer JJ; Desimone JA Pharmacotherapy; 2014 May; 34(5):506-20. PubMed ID: 24347095 [TBL] [Abstract][Full Text] [Related]
3. [Integrase inhibitors - new challenges for the treatment of HIV-1 infections]. Stock I Med Monatsschr Pharm; 2013 Dec; 36(12):448-59; quiz 461-2. PubMed ID: 24450269 [TBL] [Abstract][Full Text] [Related]
4. Dolutegravir, a second-generation integrase inhibitor for the treatment of HIV-1 infection. Rathbun RC; Lockhart SM; Miller MM; Liedtke MD Ann Pharmacother; 2014 Mar; 48(3):395-403. PubMed ID: 24259658 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy of dolutegravir in treatment-experienced patients: the SAILING and VIKING trials]. Moreno S; Berenguer J Enferm Infecc Microbiol Clin; 2015 Mar; 33 Suppl 1():26-30. PubMed ID: 25858609 [TBL] [Abstract][Full Text] [Related]
6. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Cahn P; Pozniak AL; Mingrone H; Shuldyakov A; Brites C; Andrade-Villanueva JF; Richmond G; Buendia CB; Fourie J; Ramgopal M; Hagins D; Felizarta F; Madruga J; Reuter T; Newman T; Small CB; Lombaard J; Grinsztejn B; Dorey D; Underwood M; Griffith S; Min S; Lancet; 2013 Aug; 382(9893):700-8. PubMed ID: 23830355 [TBL] [Abstract][Full Text] [Related]
7. Potential benefit of dolutegravir once daily: efficacy and safety. Fantauzzi A; Turriziani O; Mezzaroma I HIV AIDS (Auckl); 2013; 5():29-40. PubMed ID: 23413040 [TBL] [Abstract][Full Text] [Related]
8. Dolutegravir: clinical efficacy and role in HIV therapy. Fantauzzi A; Mezzaroma I Ther Adv Chronic Dis; 2014 Jul; 5(4):164-77. PubMed ID: 24982751 [TBL] [Abstract][Full Text] [Related]
9. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Raffi F; Rachlis A; Stellbrink HJ; Hardy WD; Torti C; Orkin C; Bloch M; Podzamczer D; Pokrovsky V; Pulido F; Almond S; Margolis D; Brennan C; Min S; Lancet; 2013 Mar; 381(9868):735-43. PubMed ID: 23306000 [TBL] [Abstract][Full Text] [Related]
10. Dolutegravir: a next-generation integrase inhibitor for treatment of HIV infection. Osterholzer DA; Goldman M Clin Infect Dis; 2014 Jul; 59(2):265-71. PubMed ID: 24723281 [TBL] [Abstract][Full Text] [Related]
11. Review of integrase strand transfer inhibitors for the treatment of human immunodeficiency virus infection. Park TE; Mohamed A; Kalabalik J; Sharma R Expert Rev Anti Infect Ther; 2015; 13(10):1195-212. PubMed ID: 26293294 [TBL] [Abstract][Full Text] [Related]
12. Evolution of a novel pathway leading to dolutegravir resistance in a patient harbouring N155H and multiclass drug resistance. Hardy I; Brenner B; Quashie P; Thomas R; Petropoulos C; Huang W; Moisi D; Wainberg MA; Roger M J Antimicrob Chemother; 2015 Feb; 70(2):405-11. PubMed ID: 25281399 [TBL] [Abstract][Full Text] [Related]
13. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial. Raffi F; Jaeger H; Quiros-Roldan E; Albrecht H; Belonosova E; Gatell JM; Baril JG; Domingo P; Brennan C; Almond S; Min S; Lancet Infect Dis; 2013 Nov; 13(11):927-35. PubMed ID: 24074642 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. Quashie PK; Oliviera M; Veres T; Osman N; Han YS; Hassounah S; Lie Y; Huang W; Mesplède T; Wainberg MA J Virol; 2015 Mar; 89(6):3163-75. PubMed ID: 25552724 [TBL] [Abstract][Full Text] [Related]
15. Combination of two pathways involved in raltegravir resistance confers dolutegravir resistance. Malet I; Thierry E; Wirden M; Lebourgeois S; Subra F; Katlama C; Deprez E; Calvez V; Marcelin AG; Delelis O J Antimicrob Chemother; 2015 Oct; 70(10):2870-80. PubMed ID: 26205139 [TBL] [Abstract][Full Text] [Related]
16. Antiretroviral therapy with integrase inhibitors: more options. Raffi F; Wainberg MA Virologie (Montrouge); 2013 Apr; 17(2):54-60. PubMed ID: 31910534 [TBL] [Abstract][Full Text] [Related]
17. High frequency of dolutegravir resistance in patients failing a raltegravir-containing salvage regimen. Cavalcanti Jde S; Ferreira JL; Guimarães PM; Vidal JE; Brigido LF J Antimicrob Chemother; 2015 Mar; 70(3):926-9. PubMed ID: 25386009 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Integrase Inhibitors in Antiretroviral-Naive Patients. D'Abbraccio M; Busto A; De Marco M; Figoni M; Maddaloni A; Abrescia N AIDS Rev; 2015; 17(3):171-85. PubMed ID: 26450805 [TBL] [Abstract][Full Text] [Related]
19. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Mesplède T; Quashie PK; Zanichelli V; Wainberg MA Ann Med; 2014 May; 46(3):123-9. PubMed ID: 24579911 [TBL] [Abstract][Full Text] [Related]
20. Newly approved integrase inhibitors for clinical treatment of AIDS. Gu WG Biomed Pharmacother; 2014 Oct; 68(8):917-21. PubMed ID: 25451165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]